Granulocyte colony-stimulating factor (G-CSF) 7 and is closely correlated with cytopenia. To date, no factor is availgranulocyte-macrophage colony-stimulating factor (GM- platelet maturation and is able to enhance platelet production
also mainly occurs outside the hemopoietic system, namely in liver and kidney. We are only beginning to understand the mechanism behind the regulation of TPO expression, but it Introduction appears more and more obvious that TPO concentration is regulated post-transcriptionally. 20 Primary myelodysplastic syndromes (MDS) represent a clonal In order to study TPO regulation in MDS patients with a disorder of an early hemopoietic progenitor cell, 1 leading to view to potential future clinical trials, we measured endogenabnormal maturation of all hemopoietic cell lines. With ous TPO concentrations and aimed to correlate them with expansion of the malignant clone, progressive cytopenia megakaryocyte and platelet count. reflecting ineffective hemopoiesis develops and the tendency for transition to overt leukemia increases. Prognosis in MDS is closely correlated not only with bone marrow blast cell Materials and methods count 2 and cytogenetic abnormalities 3 but also with cytopenia, 4 causing an increased risk of lethal bleeding or infecPatient characteristics tion. Although many clinical trials have been performed with difSerum samples were obtained from 69 patients suffering from ferentiating agents, 5 low-dose cytosine-arabinoside (LD Araprimary myelodysplastic syndromes. Patients' characteristics C) 5 or intensive chemotherapy, 6 no generally accepted treatare shown in Tables 1-3 . Classification of MDS was performent is available for MDS except allogeneic bone marrow med according to FAB criteria. 2 Twenty-six patients presented transplantation. In the majority of cases, the need for therapy with refractory anemia (RA), 12 with refractory anemia with is dictated not by development overt leukemia, but by dysexcess of blasts (RAEB), 25 with refractory anemia with excess hemopoiesis leading to anemia, neutropenia and/or thromof blasts in transition (RAEBt), and six with chronic bocytopenia. Thus, several clinical trials have investigated the myelomonocytic leukemia (CMML). All collected sera were effect of hemopoietic growth factors in MDS.
stored at −20°C until use. Blood count including differential count was determined for all patients from the same date. None of the patients suffered from infection or had received months. Blood count including differential count was avail- In order to have objective data and to exclude smears with an insufficient number of bone marrow particles, megakarytest, correlation analysis with Spearman's rank correlation test. A P value of 0.05 or less was deemed a significant correlation. ocyte count was evaluated by two independent blinded reviewers in 10 fields of view using 10-fold magnification. Results were scored according to three categories: absent or reduced megakaryopoiesis (average of р2 megakaryocytes), Results normal (3-4 megakaryocytes), and elevated (Ͼ4 megakaryocytes). 21 Thrombopoietin serum concentrations Samples obtained from 60 healthy individuals with a normal platelet number had been previously shown to be below Detection of endogenous TPO concentrations detectable TPO concentrations. 22 In our series of 69 MDS patients, platelet counts ranged from 2 to 526 × 10 9 /l (mean Serum concentrations of TPO in MDS patients were determined using a TPO receptor-based ELISA. 22 Briefly, ELISA 112 × 10 9 /l). Elevated endogenous TPO serum concentrations between 187 and 2137 pg/ml (mean 731 pg/ml) were detected plates were incubated with rabbit F(ab′) 2 anti-human Fc (2 g/ml) at 4°C overnight and then with a chimeric mpl-IgG in 14 patients. Of the 53 patients from whom cytogenetic data were available, 23 patients (43.4%) showed cytogenetic consisting of the cellular domain of TPO receptor fused to the Fc portion of human IgG (100 ng/ml) for 2 h. Standards and anomalies.
60
In none of the FAB groups described below, was a corretwo-fold serial dilutions of samples (final dilution range 1:5 to 1:40) were incubated on the plate for 1 h. Bound TPO was lation found between TPO serum concentrations and leukocytes, hemoglobin, patient age or cytogenetic anomalies. detected using biotinylated rabbit antibody to full length TPO, followed by peroxidase-labeled streptavidin and 3,3′,5,5′-Also, no correlation was detected between TPO concentration and neutrophil, monocyte or lymphocyte count (data not tetramethyl benzidine as the substrate. Recombinant fulllength TPO produced in mammalian cells was used as the shown). UPN, unique patient number; MP, megakaryopoiesis (1 = decreased; 2 = normal, 3 = increased); lts, less than standard; ND, not done a NA, not available. ELISA signals were seen but were not specific to mpl-IgG; similar or higher signals were seen when the non-relevant CD4-IgG was used instead of mpl-IgG in the ELISA. 110 × 10 9 /l), and in the 25 RAEBt patients the range was from 4 to 375 × 10 9 /l (mean 122 × 10 9 /l). An elevated endogenous UPN, unique patient number; MP, megakaryopoiesis; lts, less than TPO concentration was detected in one of 12 RAEB patients standard; ND, not done.
(220 pg/ml) and in two of 25 RAEBt patients (245 and 400 pg/ml). No correlation between TPO concentration and platelet count was found in either group of patients. Of the Refractory anemia (RA):
In 26 patients with refractory aneRAEBt patients, nine showed a peripheral blast cell count mia (RA) (Table 1), platelet counts ranged from 2 to у5% (between 5 and 22%; mean 14%). One of these patients 526 × 10 9 /l (mean 129 × 10 9 /l). Ten of the 26 serum samples with a platelet count of 108 × 10 9 /l showed an elevated TPO showed elevated TPO serum concentrations ranging from 187 concentration of 245 pg/ml. to 2137 pg/ml (mean 808 pg/ml). Only two of the patients with measurable TPO value demonstrated a platelet count above 65 × 10 9 /l (117 and 150 × 10 9 /l). A significant correlation (P = 0.004) between low platelet count and high Chronic myelomonocytic leukemia (CMML): In CMML were only found when megakaryopoiesis was decreased.
Only one RA patient with normal megakaryopoiesis demonstrated a slightly elevated TPO concentration of 187 pg/ml. As determined by 2 test, in patients with decreased megakaryopoiesis TPO serum concentrations were significantly (P = 0.015) more often increased in RA (eight of 12 patients) than in RAEB/RAEBt (four of 18 patients). No correlation of TPO serum concentrations and dysmegakaryopoiesis was detected.
Discussion
The majority of MDS patients die from the consequences of severe cytopenia, thus making it an important prognostic factor. 4 Beside lethal infections and the consequences of anemia, bleeding too, can lead to severe and even lethal complications in MDS patients. Primary causes of thrombocytopenia in MDS Figure 1 Endogenous TPO serum concentrations (pg/ml) in relation to megakaryopoiesis in the bone marrow in patients with RA.
include ineffective hemopoiesis, 23 impaired responsiveness to Elevated TPO concentrations were found in eight out of 12 patients growth factor stimulation, 24 and inhibitory mechanisms with decreased megakaryopoiesis and in only one out of the eight mediated by microenvironmental conditions including tumor patients with normal or increased megakaryopoiesis.
necrosis factor. 25 To date, no hemopoietic growth factor is available which reliably increases platelet count in MDS patients in vivo. (Table 3) , platelet counts ranged from 14 to 393 × 10 9 /l (mean Recently, TPO was cloned and found to be the major regulator 143 × 10 9 /l). In no patients were increased TPO serum conof megakaryopoiesis. 19 In the sera of thrombocytopenic anicentrations measured. mals, TPO concentration varies inversely with platelet count. 26 In order to investigate response in thrombopenic MDS Megakaryocyte count patients, we measured endogenous TPO serum concentrations in patients with different stages of MDS according to FAB Megakaryocyte count in the bone marrow represents an
classification. An inverse correlation between TPO concenobjective parameter for overall megakaryopoietic activity. In tration and platelet count could only be detected in patients healthy individuals, three to four megakaryocytes per lowwith refractory anemia, while no significant correlation was power field are generally observed 21 by light microscopy. Our found in the more progressed stages or in CMML patients. series contained bone marrow samples from 64 patients (21 Spike recovery studies of selected patient samples with absent RA, 12 RAEB, 25 RAEBt, six CMML). Megakaryocytes were or decreased megakaryocytes from RA, RAEB, RAEBt and absent or decreased in 34 patients (13 RA, seven RAEB, 11
CMML patients did not demonstrate any substance interfering RAEBt, three CMML), normal in 18 patients (four RA, nine with the ELISA. RAEB, four RAEBt, one CMML) and, increased in 12 patients Tissue analysis in animals shows that thrombopoietin (four RA, one RAEB, five RAEBt, two CMML).
mRNA is expressed primarily in liver, kidney and smooth musAs shown in Figures 1 and 2 , both in patients with RA or cle, with lesser amounts present in spleen and bone mar-RAEB/RAEBt, significantly elevated TPO serum concentrations row. 17, 18 In this respect TPO production resembles EPO which is also mainly produced outside the hemopoietic system.
Although clinical trials with TPO are already in progress, full understanding of the interactions of TPO and its target cells at the molecular level remains to be achieved. TPO production seems to be regulated at the post-transcriptional level and is not yet fully understood. There is increasing evidence that the rate of TPO gene expression is constant and that plasma concentrations are entirely dependent on the rate of receptor-mediated TPO uptake and destruction by platelets. 20 Therefore, when platelet levels are high, TPO is rapidly destroyed and circulating concentrations decrease, thereby limiting megakaryocyte production. Also, TPO-specific bone marrow mRNA levels are inversely related to platelet count. 27 It may therefore be argued that although liver and kidney contain quantitatively more TPO transcripts, marrow may be a more physiologically relevant source and serum immunoreactive TPO concentrations may not necessarily reflect biological ated by a decrease of circulating platelet counts. 
